Alleles and genotypes of polymorphisms of IL-18, TNF-α and IFN-γ are associated with a higher risk and severity of hepatocellular carcinoma (HCC) in Brazil

Human Immunology

Volumn 74, Issue 8, 2013, Pages 1024-1029

  Teixeira, A C ^a   Mendes Junior, C T ^a   Marano, L A ^a   Deghaide, N H S ^a   Secaf, M ^a   Elias Junior, J ^a   Muglia, V ^a   Donadi, E A ^a   Martinelli, A L C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 18; SILVER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; BRAZIL; CANCER RISK; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ALLELES; BRAZIL; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-18; LIVER NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; RISK; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84879878198     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2013.04.029     Document Type: Article

References (33)

1. Bosh F.X., Ribes J., Díaz M., Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterol 2004, 127(5):5-16. Supplement 1.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer Statistics. CA: a Cancer J Clin 2009, 59(4):225-249.
3. Budhu A., Wang X.W. The role of cytokines in hepatocellular carcinoma. J Leukoc Biol 2006, 80:1197-1213.
4. Bidwell J., Keen L., Gallagher G., Kimberly R., Huizinga T., McDermott M.F., et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 2001, 2:61-70.
5. Bayley J.P., Ottenhoff T.H., Verweij C.L. Is there a future for TNF promoter polymorphisms?. Genes Immun 2004, 5:315-329.
6. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001, 35:421-430.
7. Bruix J., Sherman M. AASLD practice guideline. Management of hepatocellular carcinoma. Hepatol 2005, 42:1208-1236.
8. Miller A.S. A simple salting out procedure for extracting DNA for human nucleated cells. Nucleic Acids Res 1988, 16:1215.
9. Castelar L., Silva M.M., Castelli E.C., Deghaide N.H., Mendes-Junior C.T., Machado A.A., et al. Interleukin-18 and interferon-gamma polymorphisms in Brazilian human immunodeficiency virus-1-infected patients presenting with lipodystrophy syndrome. Tissue Antigens 2010 Aug, 76(2):126-130.
10. Marsh H.P., Haldar N.A., Bunce M., Marshall S.E., le Monier K., Winsey S.L., et al. Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation. Br J Cancer 2003, 89(6):1096-1101.
11. Pravica V., Perrey C., Stevens A., Lee J.-H., Hutchinson I.V. A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Human Immunol 2000, 61(9):863-866.
12. Guo S.W., Thompson E.A. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992, 48:361-372.
13. Rousset F. GENEPOP'007: a complete reimplementation of the Genepop software for Windows and Linux. Mol Ecol Resour 2008, 8:103-106.
14. Excoffier L., Laval G., Schneider S. ARLEQUIN VER. 3.0: an integrated software package for population genetics data analysis. Evolutionary bioinformatics online 2005, 1:47-50.
15. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J. Hum Genet 2001, 68(4):978-989.
16. Excoffier L., Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995, 12:921-927.
17. Mi Y.Y., Yu Q.Q., Yu M.L., Xu B., Zhang L.F., Cheng W., et al. Review and pooled analysis of studies on -607(C/A) and -137(G/C) polymorphisms in IL-18 and cancer risk. Med Oncol. 2011, 28(4):1107-1115.
18. Migita K., Miyazoe S., Maeda Y., Daikoku M., Abiru S., Ueki T., et al. Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGF-beta1 polymorphisms and hepatocellular carcinoma. J Hepatol 2005, 42:505-510.
19. Akkiz H., Bayram S., Bekar A., Ozdil B., Akgöllü E., Sümbül A.T., et al. G-308A TNF-alpha polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol 2009, 33:261-264.
20. Jung K.W., Ha E., Yu G.I., Kim S.J., Chung W.J., Jang B.K., et al. TNFalpha promoter polymorphism is a risk factor for susceptibility in hepatocellular carcinoma in Korean population. Clin Chim Acta 2009, 407:16-19.
21. Yang Y., Qiu X.Q., Yu H.P., Zeng X.Y., Bei C.H. TNF-α -863 polymorphisms and the risk of hepatocellular carcinoma. Exp Ther Med 2012, 3(3):513-518.
22. Abraham L.J., Kroeger K.M. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 1999, 66:562-566.
23. Sáenz-López P., Carretero R., Vazquez F., Martin J., Sánchez E., Tallada M., et al. Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol 2010, 71(3):309-313.
24. Haghshenas M.R., Hosseini S.V., Mahmoudi M., Saberi-Firozi M., Farjadian S., Ghaderi A. IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol 2009, 26(6):1119-1122.
25. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 2001, 12(1):53-72.
26. Mojtahedi Z. Interleukin (IL)-18 may enhance Th1 response in early cancer but aggravate malignant disease in its later stages. Med Hypotheses 2005, 65(5):995-996.
27. Tangkijvanich P., Thong-Ngam D., Machachai V., Theamboonlers A., Poovorawan Y. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 2007, 13(32):4345-4349.
28. Bouzgarrou N., Hassen E., Farhat K., Bahri O., Gabbouj S., Maamouri N., et al. Combined analysis of interferon-gamma and interleukin-10 gene polymorphisms and chronic hepatitis C severity. Hum Immunol 2009, 70(4):230-236.
29. Du Y., Xie J., Chang W., Han Y., Cao G. Genome-wide association studies: inherent limitations and future challenges. Front Med 2012, 6(4):444-450.
30. Zhang H., Zhai Y., Hu Z., Wu C., Qian J., Jia W., et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010, 42(9):755-758.
31. Li S., Qian J., Yang Y., Zhao W., Dai J., Bei J.X., et al. GWASidentifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 2012, 8(7):e1002791.
32. Kumar V., Kato N., Urabe Y., Takahashi A., Muroyama R., Hosono N., et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011, 43(5):455-458.
33. Miki D., Ochi H., Hayes C.N., Aikata H., Chayama K. Hepatocellular carcinoma: towards personalized medicine. Cancer Sci 2012, 103(5):846-850.